| A Study in Patients With Advanced Breast Cancer (NCT04942054) | Sun Pharma Advanced Research Company Limited | 2022-05-20 |
| RWE About QOL and Compliance of Patients With OFS in China (NCT05122377) | Fudan University | 2022-03-01 |
| Promoting Physical Activity in Breast Cancer Survivors on Aromatase Inhibitors (NCT05860621) | Grupo Lusófona | 2022-01-05 |
| Study of Screening Brain MRIs in Stage IV Breast Cancer (NCT05115474) | H. Lee Moffitt Cancer Center and Research Institute | 2021-12-21 |
| ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer (NCT06570031) | Ono Pharmaceutical Co., Ltd. | 2021-11-09 |
| Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients (NCT04997941) | Seoul National University Hospital | 2021-10-21 |
| Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer (NCT05064085) | H. Lee Moffitt Cancer Center and Research Institute | 2021-10-12 |
| ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer (NCT04602117) | QuantumLeap Healthcare Collaborative | 2021-07-28 |
| Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial (NCT05165225) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2021-07-13 |
| Study of XB002 in Subjects With Solid Tumors (JEWEL-101) (NCT04925284) | Exelixis | 2021-06-07 |
| Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer (NCT04891731) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2021-05-01 |
| Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer (NCT04872985) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2021-04-20 |
| TH1902 in Patients With Advanced Solid Tumors (NCT04706962) | Theratechnologies | 2021-03-04 |
| A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (NCT04569747) | Dana-Farber Cancer Institute | 2021-01-11 |
| Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study (NCT06463626) | Novartis | 2020-04-06 |
| WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor (NCT03854903) | Georgetown University | 2019-04-01 |
| First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) (NCT03401385) | Daiichi Sankyo Co., Ltd. | 2018-01-31 |
| CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO (NCT03227328) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2017-08-02 |
| A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer (NCT02675231) | Eli Lilly and Company | 2016-05-23 |
| Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (NCT01698918) | Novartis Pharmaceuticals | 2013-03-07 |
| A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. (NCT01602380) | AstraZeneca | 2012-10-17 |
| Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma (NCT01177397) | Celgene | 2010-07-20 |
| Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer (NCT00615524) | GlaxoSmithKline | 2008-04-01 |